Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

NCT06502743 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT06502743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06502743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer
Lead sponsor
Yonsei University
Phase
Phase 2
Overall status
Recruiting
Start date
September 12, 2024
Completion date
December 31, 2027
Enrollment
92 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, endometrial carcinoma, endometrial neoplasms, gynecologycal cancer, recurrent endometrial carcinoma